DMK · Dmk Pharmaceuticals Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1K | $6.9K | $1.45M | - | $1.51M | $39.8K | $1.15M | - | $760.0K | $4.01M |
| Cost of Revenue | $338.5K | $361.4K | $1.79M | - | $1.65M | $689.2K | $1.46M | - | $1.24M | $3.87M |
| Gross Profit | ($329.4K) | ($354.4K) | ($335.1K) | - | ($141.9K) | ($649.3K) | ($309.1K) | - | ($475.6K) | $140.7K |
| R&D | $1.98M | $3.32M | $1.31M | - | $1.98M | $3.32M | $4.22M | - | $4.62M | $2.23M |
| SG&A | $2.52M | $4.03M | $4.78M | - | $2.51M | $4.21M | $3.38M | - | $4.79M | $7.13M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $67.0K | $87.0K | $109.5K | - | $399.0K | $368.0K | $344.2K | - | $375.0K | $678.6K |
| Operating Income | ($3.27M) | ($11.30M) | ($6.43M) | - | ($4.63M) | ($8.18M) | ($7.91M) | - | ($10.22M) | ($9.23M) |
| Interest Expense | $29.5K | $46.3K | - | - | - | - | - | - | $1.9K | $44.9K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.39M) | ($8.57M) | ($8.94M) | - | ($4.40M) | ($8.40M) | ($10.35M) | - | ($12.36M) | ($9.31M) |
| EPS - Basic | ($0.20) | ($3.40) | ($0.06) | - | ($0.03) | ($0.06) | ($0.12) | - | - | - |
| EPS - Diluted | ($0.20) | ($3.40) | ($0.06) | - | ($0.03) | ($0.06) | ($0.12) | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.66M | $640.3K | $3.10M | $1.08M | $2.42M | $8.88M | $17.77M | $23.22M | $28.73M | $40.62M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $663.0K | $664.4K | $664.4K | $1.24M | $1.09M | $440.2K | $32.0K | $418.6K | - | $2.17M |
| Accounts Payable | $9.97M | $11.37M | $9.78M | $7.94M | $5.30M | $4.52M | $4.89M | $3.75M | $2.45M | $3.01M |
| Current Assets | $7.87M | $3.45M | $7.55M | $9.27M | $10.09M | $15.32M | $27.79M | $35.20M | $41.90M | $46.13M |
| Total Assets | $8.96M | $4.75M | $9.08M | $10.93M | $12.14M | $17.69M | $30.55M | $38.30M | $45.08M | $63.71M |
| Current Liabilities | $13.46M | $15.01M | $12.95M | $11.40M | $8.87M | $9.72M | $13.58M | $11.22M | $9.20M | $13.45M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $1.57M |
| Total Liabilities | $13.92M | $16.24M | $18.60M | $11.58M | $9.13M | $10.65M | $14.65M | $12.42M | $10.61M | $17.03M |
| Stockholders' Equity | ($5.29M) | ($11.83M) | ($9.68M) | ($808.1K) | $2.85M | $7.04M | $15.90M | $25.88M | $46.68M | - |
| Retained Earnings | ($323.47M) | ($322.08M) | ($313.51M) | ($304.56M) | ($301.24M) | ($296.84M) | ($288.44M) | ($278.09M) | ($269.31M) | ($256.95M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($1.55M) | - | - | - | ($6.99M) | - | - | - |
| Investing Cash Flow | - | - | $841.8K | - | - | - | $1.53M | - | - | - |
| Financing Cash Flow | - | - | $2.72M | - | - | - | $56.04M | - | - | - |
| CapEx | - | - | - | - | - | - | $26.9K | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | ($7.01M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -3635.2% | -5103.7% | -23.1% | - | -9.4% | -1629.6% | -26.8% | - | -62.6% | 3.5% |
| Operating margin | -36030.7% | -162766.9% | -442.4% | - | -307.4% | -20518.3% | -685.4% | - | -1344.9% | -230.2% |
| EBITDA margin | -35291.4% | -161514.2% | -434.8% | - | -280.9% | -19594.7% | -655.6% | - | -1295.5% | -213.3% |
| Net margin | -15317.2% | -123457.5% | -615.5% | - | -292.2% | -21073.7% | -896.9% | - | -1626.5% | -232.2% |
| Free cash flow margin | - | - | - | - | - | - | -607.4% | - | - | - |
| FCF / Net income | - | - | - | - | - | - | 0.68 | - | - | - |
| R&D / Revenue | 21826.7% | 47813.6% | 90.2% | - | 131.4% | 8333.5% | 365.7% | - | 607.9% | 55.7% |
| SG&A / Revenue | 27777.1% | 58071.7% | 329.1% | - | 166.6% | 10555.2% | 293.0% | - | 630.9% | 177.8% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -15.5% | -180.5% | -98.5% | - | -36.2% | -47.5% | -33.9% | - | -27.4% | -14.6% |
| Return on equity | 26.2% | 72.5% | 92.4% | - | -154.6% | -119.2% | -65.1% | - | -26.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.58 | 0.23 | 0.58 | 0.81 | 1.14 | 1.58 | 2.05 | 3.14 | 4.56 | 3.43 |
| Quick ratio | 0.54 | 0.19 | 0.53 | 0.70 | 1.01 | 1.53 | 2.04 | 3.10 | 4.56 | 3.27 |
| Cash ratio | 0.49 | 0.04 | 0.24 | 0.09 | 0.27 | 0.91 | 1.31 | 2.07 | 3.12 | 3.02 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.02 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -110.8x | -244.1x | - | - | - | - | - | - | -5480.2x | -205.4x |
| Equity multiplier | -1.69 | -0.40 | -0.94 | -13.53 | 4.27 | 2.51 | 1.92 | 1.48 | 0.97 | - |
| Liabilities / Assets | 1.55 | 3.42 | 2.05 | 1.06 | 0.75 | 0.60 | 0.48 | 0.32 | 0.24 | 0.27 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.16 | - | 0.12 | 0.00 | 0.04 | - | 0.02 | 0.06 |
| Inventory turnover | 0.51 | 0.54 | 2.69 | - | 1.51 | 1.57 | 45.74 | - | - | 1.78 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 715d | 671d | 136d | - | 242d | 233d | 8d | - | - | 205d |
| Days payable outstanding | 10755d | 11479d | 1997d | - | 1174d | 2392d | 1220d | - | 725d | 284d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -99.4% | -82.6% | 25.9% | - | 98.1% | -99.0% | -71.9% | - | -82.3% | -30.4% |
| Revenue CAGR (3y) | -87.2% | -89.4% | -32.2% | - | -36.6% | -81.0% | -28.7% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | -15.0% | -59.8% | -17.6% | - | -18.2% | 15.8% |
| Gross profit growth (YoY) | -132.2% | 45.4% | -8.4% | - | 70.2% | - | - | - | - | - |
| Operating income growth (YoY) | 29.4% | -38.3% | 18.8% | - | 54.7% | 11.4% | -2.6% | - | -49.4% | 17.9% |
| Net income growth (YoY) | 68.4% | -2.1% | 13.6% | - | 64.4% | 9.8% | 32.7% | - | -65.1% | 17.3% |
| EPS growth (YoY) | -566.7% | -5566.7% | 50.0% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | -41.9% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | -93.9% | - | -71.2% | 640.0% | 70.4% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Business segments
$16.53M totalCompounded Pharmaceuticals$13.75M · 83.2%
Drug Development And Commercialization$2.78M · 16.8%
Product / service
$30.28M totalCompounded Pharmaceuticals$13.75M · 45.4%
Sterile Product$9.16M · 30.3%
Non Sterile Product$4.59M · 15.1%
Manufactured Product Other$2.78M · 9.2%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing DMK PHARMACEUTICALS Corp against the 5 most active filers in the same SIC group.